These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
181 related articles for article (PubMed ID: 34094032)
21. Tachykinin Receptor-Selectivity of the Potential Glioblastoma-Targeted Therapy, DOTA-[Thi Suthiram J; Pieters A; Mohamed Moosa Z; Zeevaart JR; Sathekge MM; Ebenhan T; Anderson RC; Newton CL Int J Mol Sci; 2023 Jan; 24(3):. PubMed ID: 36768456 [TBL] [Abstract][Full Text] [Related]
22. Neurokinin-1 Receptor (NK-1R) Antagonists: Potential Targets in the Treatment of Glioblastoma Multiforme. Afshari AR; Motamed-Sanaye A; Sabri H; Soltani A; Karkon-Shayan S; Radvar S; Javid H; Mollazadeh H; Sathyapalan T; Sahebkar A Curr Med Chem; 2021; 28(24):4877-4892. PubMed ID: 33441062 [TBL] [Abstract][Full Text] [Related]
23. The substance P/ neurokinin-1 receptor signaling pathway mediates metastasis in human colorectal SW480 cancer cells. Golestaneh M; Firoozrai M; Javid H; Hashemy SI Mol Biol Rep; 2022 Jun; 49(6):4893-4900. PubMed ID: 35429316 [TBL] [Abstract][Full Text] [Related]
24. MiR-34b/c-5p and the neurokinin-1 receptor regulate breast cancer cell proliferation and apoptosis. Zhang L; Wang L; Dong D; Wang Z; Ji W; Yu M; Zhang F; Niu R; Zhou Y Cell Prolif; 2019 Jan; 52(1):e12527. PubMed ID: 30334298 [TBL] [Abstract][Full Text] [Related]
25. Corneal lymphangiogenesis in dry eye disease is regulated by substance P/neurokinin-1 receptor system through controlling expression of vascular endothelial growth factor receptor 3. Lee SJ; Im ST; Wu J; Cho CS; Jo DH; Chen Y; Dana R; Kim JH; Lee SM Ocul Surf; 2021 Oct; 22():72-79. PubMed ID: 34311077 [TBL] [Abstract][Full Text] [Related]
26. Aprepitant inhibits the progression of esophageal squamous cancer by blocking the truncated neurokinin‑1 receptor. Zheng Y; Sang M; Liu F; Gu L; Li J; Wu Y; Shan B Oncol Rep; 2023 Jul; 50(1):. PubMed ID: 37203393 [TBL] [Abstract][Full Text] [Related]
27. Substance P receptor antagonists in psychiatry: rationale for development and therapeutic potential. Herpfer I; Lieb K CNS Drugs; 2005; 19(4):275-93. PubMed ID: 15813642 [TBL] [Abstract][Full Text] [Related]
28. Anti-HIV-1 activity of the neurokinin-1 receptor antagonist aprepitant and synergistic interactions with other antiretrovirals. Manak MM; Moshkoff DA; Nguyen LT; Meshki J; Tebas P; Tuluc F; Douglas SD AIDS; 2010 Nov; 24(18):2789-96. PubMed ID: 20975512 [TBL] [Abstract][Full Text] [Related]
29. Substance P Receptor Antagonist Suppresses Inflammatory Cytokine Expression in Human Disc Cells. Kepler CK; Markova DZ; Koerner JD; Mendelis J; Chen CM; Vaccaro AR; Risbud MV; Albert TJ; Anderson DG Spine (Phila Pa 1976); 2015 Aug; 40(16):1261-9. PubMed ID: 25929203 [TBL] [Abstract][Full Text] [Related]
30. Substance P promotes the recovery of oxidative stress-damaged retinal pigmented epithelial cells by modulating Akt/GSK-3β signaling. Baek SM; Yu SY; Son Y; Hong HS Mol Vis; 2016; 22():1015-23. PubMed ID: 27582624 [TBL] [Abstract][Full Text] [Related]
31. Analog of somatostatin vapreotide exhibits biological effects in vitro via interaction with neurokinin-1 receptor. Spitsin S; Tuluc F; Meshki J; Ping Lai J; Tustin Iii R; Douglas SD Neuroimmunomodulation; 2013; 20(5):247-55. PubMed ID: 23921645 [TBL] [Abstract][Full Text] [Related]
32. Menadione Potentiates Auranofin-Induced Glioblastoma Cell Death. Szeliga M; Rola R Int J Mol Sci; 2022 Dec; 23(24):. PubMed ID: 36555352 [TBL] [Abstract][Full Text] [Related]
33. Substance P and the Neurokinin-1 Receptor: The New CRF. Schank JR; Heilig M Int Rev Neurobiol; 2017; 136():151-175. PubMed ID: 29056150 [TBL] [Abstract][Full Text] [Related]
34. Brain mitochondria from DJ-1 knockout mice show increased respiration-dependent hydrogen peroxide consumption. Lopert P; Patel M Redox Biol; 2014; 2():667-72. PubMed ID: 24936441 [TBL] [Abstract][Full Text] [Related]
35. Understanding the survival mechanisms of Deinococcus radiodurans against oxidative stress by targeting thioredoxin reductase redox system. Maqbool I; Ponniresan VK; Govindasamy K; Prasad NR Arch Microbiol; 2020 Nov; 202(9):2355-2366. PubMed ID: 31570971 [TBL] [Abstract][Full Text] [Related]
36. Targeting the neurokinin-1 receptor inhibits growth of human colon cancer cells. Garnier A; Vykoukal J; Hubertus J; Alt E; von Schweinitz D; Kappler R; Berger M; Ilmer M Int J Oncol; 2015 Jul; 47(1):151-60. PubMed ID: 25998227 [TBL] [Abstract][Full Text] [Related]
37. New insight into the role of substance P/neurokinin-1 receptor system in breast cancer progression and its crosstalk with microRNAs. Ebrahimi S; Javid H; Alaei A; Hashemy SI Clin Genet; 2020 Oct; 98(4):322-330. PubMed ID: 32266968 [TBL] [Abstract][Full Text] [Related]
38. Discovery of a New CaMKII-Targeted Synthetic Lethal Therapy against Glioblastoma Stem-like Cells. Han JM; Kim YJ; Jung HJ Cancers (Basel); 2022 Mar; 14(5):. PubMed ID: 35267623 [TBL] [Abstract][Full Text] [Related]
39. Tissue and plasma thioredoxin reductase expressions in patients with glioblastoma multiforme. Kemerdere R; Kacira T; Hanimoglu H; Kucur M; Tanriverdi T; Canbaz B J Neurol Surg A Cent Eur Neurosurg; 2013 Jul; 74(4):234-8. PubMed ID: 23512591 [TBL] [Abstract][Full Text] [Related]
40. Differential consequences of neurokinin receptor 1 and 2 antagonists in metastatic breast carcinoma cells; Effects independent of Substance P. Nizam E; Erin N Biomed Pharmacother; 2018 Dec; 108():263-270. PubMed ID: 30223097 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]